MX2024004429A - Regimenes de dosificacion del anticuerpo anti-ctla-4. - Google Patents

Regimenes de dosificacion del anticuerpo anti-ctla-4.

Info

Publication number
MX2024004429A
MX2024004429A MX2024004429A MX2024004429A MX2024004429A MX 2024004429 A MX2024004429 A MX 2024004429A MX 2024004429 A MX2024004429 A MX 2024004429A MX 2024004429 A MX2024004429 A MX 2024004429A MX 2024004429 A MX2024004429 A MX 2024004429A
Authority
MX
Mexico
Prior art keywords
ctla
dosing regimens
antibody dosing
antibody
regimens
Prior art date
Application number
MX2024004429A
Other languages
English (en)
Spanish (es)
Inventor
Yang Liu
Pan Zheng
Martin Devenport
Original Assignee
Oncoc4 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoc4 Inc filed Critical Oncoc4 Inc
Publication of MX2024004429A publication Critical patent/MX2024004429A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2024004429A 2021-10-29 2022-10-28 Regimenes de dosificacion del anticuerpo anti-ctla-4. MX2024004429A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163273660P 2021-10-29 2021-10-29
PCT/US2022/078875 WO2023077069A1 (en) 2021-10-29 2022-10-28 Anti-ctla-4 antibody dosing regimens

Publications (1)

Publication Number Publication Date
MX2024004429A true MX2024004429A (es) 2024-05-06

Family

ID=86158833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004429A MX2024004429A (es) 2021-10-29 2022-10-28 Regimenes de dosificacion del anticuerpo anti-ctla-4.

Country Status (10)

Country Link
US (1) US20260139052A1 (cg-RX-API-DMAC7.html)
EP (1) EP4422685A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540152A (cg-RX-API-DMAC7.html)
KR (1) KR20240099187A (cg-RX-API-DMAC7.html)
CN (1) CN118176021A (cg-RX-API-DMAC7.html)
AU (1) AU2022377644A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234351A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024004429A (cg-RX-API-DMAC7.html)
TW (1) TW202325738A (cg-RX-API-DMAC7.html)
WO (1) WO2023077069A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024238912A1 (en) * 2023-05-17 2024-11-21 OncoC4, Inc. Ph-sensitive anti-ctla-4 antibodies and uses thereof
WO2026041780A2 (en) * 2024-08-23 2026-02-26 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ568016A (en) * 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
EP2912063A1 (en) * 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
LT3142751T (lt) * 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui
AU2016370648B2 (en) 2015-12-15 2023-03-09 OncoC4, Inc. Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
CN119792515A (zh) * 2018-02-13 2025-04-11 默沙东有限责任公司 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法

Also Published As

Publication number Publication date
JP2024540152A (ja) 2024-10-31
EP4422685A1 (en) 2024-09-04
TW202325738A (zh) 2023-07-01
WO2023077069A1 (en) 2023-05-04
AU2022377644A1 (en) 2024-05-16
US20260139052A1 (en) 2026-05-21
EP4422685A4 (en) 2025-12-03
KR20240099187A (ko) 2024-06-28
CN118176021A (zh) 2024-06-11
CA3234351A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
MX2020006668A (es) Anticuerpos para lilrb2.
PH12021550152A1 (en) Anti-cd112r compositions and methods
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2025002661A (es) Composiciones anti-cd24 y usos de las mismas
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
MX2024000614A (es) Anticuerpos anti-fgfr2 combinados con quimioterapia para el tratamiento del cancer.
MY195110A (en) Antibodies to PD-1 and uses Thereof
PH12018502112B1 (en) Anti-tim-3 antibodies and compositions
ZA202005388B (en) Methods of treating ulcerative colitis
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
TW201713698A (en) PD-1 antibodies
PH12016500137B1 (en) Afucosylated anti-fgfr2iiib antibodies
PH12019550233A1 (en) A novel anti-c-met antibody and use thereof
MY202870A (en) Anti-ctla-4 antibodies and uses thereof
PH12022550246A1 (en) A dosing regimen for an ido inhibitor
MX2019002728A (es) Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2021005236A (es) Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer.
BR112017011538A2 (pt) combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
PH12019502313A1 (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer